Adviser Investments LLC Buys 159 Shares of Eli Lilly and Company (NYSE:LLY)

Adviser Investments LLC raised its stake in Eli Lilly and Company (NYSE:LLYGet Rating) by 12.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,465 shares of the company’s stock after purchasing an additional 159 shares during the quarter. Adviser Investments LLC’s holdings in Eli Lilly and were worth $475,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in LLY. Pitcairn Co. boosted its position in Eli Lilly and by 9.6% during the 4th quarter. Pitcairn Co. now owns 7,265 shares of the company’s stock valued at $2,007,000 after buying an additional 635 shares during the period. Unigestion Holding SA boosted its holdings in shares of Eli Lilly and by 5.2% during the fourth quarter. Unigestion Holding SA now owns 7,600 shares of the company’s stock worth $2,099,000 after purchasing an additional 374 shares during the period. Jag Capital Management LLC grew its stake in shares of Eli Lilly and by 5.7% in the fourth quarter. Jag Capital Management LLC now owns 55,977 shares of the company’s stock worth $15,462,000 after purchasing an additional 3,002 shares during the last quarter. IHT Wealth Management LLC increased its holdings in Eli Lilly and by 1.1% during the 4th quarter. IHT Wealth Management LLC now owns 12,178 shares of the company’s stock valued at $3,364,000 after purchasing an additional 129 shares during the period. Finally, Odey Asset Management Group Ltd bought a new position in Eli Lilly and during the 4th quarter valued at approximately $2,348,000. Hedge funds and other institutional investors own 82.45% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on LLY shares. StockNews.com upgraded Eli Lilly and from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 14th. BMO Capital Markets raised their target price on shares of Eli Lilly and from $369.00 to $396.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 6th. Barclays increased their price target on shares of Eli Lilly and from $333.00 to $355.00 and gave the stock an “overweight” rating in a research note on Thursday, July 7th. UBS Group upgraded shares of Eli Lilly and from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $335.00 to $363.00 in a report on Thursday. Finally, JPMorgan Chase & Co. upped their target price on Eli Lilly and from $340.00 to $355.00 in a report on Wednesday, June 1st. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $332.19.

Eli Lilly and Trading Up 4.9 %

Shares of NYSE LLY opened at $310.87 on Friday. The company has a market cap of $295.38 billion, a PE ratio of 49.58, a P/E/G ratio of 1.92 and a beta of 0.38. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.85 and a current ratio of 1.10. The firm’s 50 day moving average price is $314.33 and its 200-day moving average price is $304.45. Eli Lilly and Company has a 52-week low of $220.20 and a 52-week high of $335.33.

Eli Lilly and (NYSE:LLYGet Rating) last issued its earnings results on Thursday, August 4th. The company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.86 by ($0.61). Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The business had revenue of $6.49 billion for the quarter, compared to analysts’ expectations of $6.85 billion. During the same quarter in the prior year, the business posted $1.87 earnings per share. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. On average, equities research analysts expect that Eli Lilly and Company will post 7.97 EPS for the current fiscal year.

Eli Lilly and Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 9th. Stockholders of record on Monday, August 15th were issued a dividend of $0.98 per share. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.26%. The ex-dividend date was Friday, August 12th. Eli Lilly and’s payout ratio is presently 62.52%.

Insider Transactions at Eli Lilly and

In other news, SVP Alonzo Weems sold 656 shares of the stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total value of $199,752.00. Following the completion of the sale, the senior vice president now directly owns 8,136 shares of the company’s stock, valued at $2,477,412. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, major shareholder Lilly Endowment Inc sold 89,458 shares of the firm’s stock in a transaction on Thursday, July 28th. The stock was sold at an average price of $332.85, for a total value of $29,776,095.30. Following the completion of the transaction, the insider now owns 103,875,441 shares in the company, valued at approximately $34,574,940,536.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Alonzo Weems sold 656 shares of the company’s stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total transaction of $199,752.00. Following the completion of the sale, the senior vice president now directly owns 8,136 shares in the company, valued at $2,477,412. The disclosure for this sale can be found here. Insiders sold 328,125 shares of company stock worth $108,581,151 over the last three months. 0.12% of the stock is currently owned by company insiders.

Eli Lilly and Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.